GWC invests in Novel Technologies Holdings Ltd as part of a £2m funding round
Greenwood Way Capital announces their latest investment in NTH, which has developed an eco-friendly antimicrobial technology. This eliminates harmful and malodorous bacteria by encapsulating pure silver within the fibres of textiles making the product antimicrobial for life.
Glasgow-based NTH was established in 2017 by David Evans, a successful life sciences entrepreneur with a wealth of sector experience. Evans identified the commercial potential of SILVERbac technology and assembled a team of industry experts to assist inventor and CTO, Zahir Ahmad, in raising capital and commercialising the technology. .
SILVERbac technology encapsulates pure silver directly into the fibres of textiles, where other products only coat fibres with silver. Silver is a natural antibacterial and can be used to inhibit disease, odour and stains. The technology has strong appeal in sectors where bacteria are common. Examples include healthcare and activewear. In healthcare SILVERbac helps to combat pathogens such as E. coli and MRSA, and in light of the current coronavirus outbreak, this is even more pivotal. SILVERBAC can be used in hospitals and other sites where protection is needed against micro-organisms including norovirus. In activewear, bacteria contained within sweat can cause stains or odours. Unlike other treatments, SILVERbac does not leach out of products, allowing consumers to wash the textiles at lower temperatures and with fewer chemicals. In addition, the company is moving rapidly into new markets including paints, coatings and oral healthcare.
Dr Stewart White, Executive Chairman of NTH, said: “I am pleased to welcome our new investors to NTH at a time when the company is poised for growth. We look forward to an exciting future enabled by the support provided by both existing and new investors in this funding round.”
Ian Leigh, GWC Founder, commented: “We are very excited about NTH’s technology and its potential applications. Recent global events have highlighted the importance of antimicrobial technology, particularly solutions for coatings and surfaces. We look forward to working with the management team and fellow investors.”
The deal was a collaboration between Greenwood Way Capital, Kelvin Capital, EOS Investment Syndicate and the Scottish Investment Bank, with additional support from Foresight.
For more information on NTH seehttp://www.silverbactech.com
GWC is a network of UHNWIs and Family Offices that invest in early stage UK companies that have disruptive technology. For further information see http://www.gwc.london